|
||
|
Decision tree for patients with CML – CP in second-line therapy with TKI trademarks (TM). |
|
||||||||
| Part of: Goranova-Marinova V, Grekova-Kafalova D, Andreevska K, Georgieva V, Gvozdeva Y, Kassarova M, Grudeva-Popova Z, Gavazova E, Petkova V (2024) Analysis of the pharmacoeconomic effectiveness of the tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia in a Single Hematology Center in Plovdiv, Bulgaria. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e126016 |